Method of treating angiogenic tissue growth

• US 20040219204A1
• Filed: 12/19/2003
• Published: 11/04/2004
• Est. Priority Date: 12/19/2002
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Huang, Ken Shi Kun, Martin, Francis J., Huang, Anthony
• Application Number:
  US10/742,074
• Publication Number:
  US 20040219204A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6913 the liposome being modified on its surface by an antibody
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A method of treating a disease or disorder characterized by angiogenic tissue growth is described. The method includes providing an immunoliposome composition comprised of (i) vesicle-forming lipids including between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer, (ii) a targeting ligand having biological activity to promote angiogenesis, and (iii) a drug entrapped in said liposomes; and administering the immunoliposome composition to a subject.

Claims

1. A method of treating a disease or disorder characterized by angiogenic tissue growth, comprising

providing an immunoliposome composition comprised of (i) vesicle-forming lipids including between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer, (ii) a targeting ligand having biological activity to promote angiogenesis, and (iii) a drug entrapped in said liposomes;

and

administering said immunoliposome composition to a subject.

2. The method of claim 1, wherein said targeting ligand is a growth factor.

3. The method of claim 2, wherein said growth factor is selected from fibroblast growth factor (FGF), epidermal growth factor (EGF), and vascular endothelial cell growth factor (VEGF).

4. The method of claim 1, wherein said drug is a chemotherapeutic agent.

5. The method of claim 4, wherein said agent is a platinum compound.

6. The method of claim 5, wherein said platinum compound is cisplatin.

7. The method of claim 1, wherein said drug is an angiogenesis inhibitor.

8. The method of claim 7, wherein said angiogenesis inhibitor is a compound selected from the group consisting of FGFR kinase inhibitors, EGFR kinase inhibitors, VEGFR kinase inhibitors, and matrix metalloproteinase inhibitors.

9. The method of claim 1, wherein said polymer is polyethylene glycol.

10. The method of claim 1, wherein said polymer is polyethylene glycol, said ligand is basic fibroblast growth factor, and said drug is a chemotherapeutic agent.

11. The method of claim 10, wherein said chemotherapeutic agent is selected from the group consisting of platinum compounds and vinca alkaloids.

12. The method of claim 1, wherein said polymer is polyethylene glycol, said ligand is basic fibroblast growth factor, and said drug is an angiogenesis inhibitor.